Entourage Health to Report Fiscal Year 2023 Financial Results
24 Abril 2024 - 3:16PM
Entourage Health Corp.
(TSX-V: ENTG) (OTCQX: ETRGF)
(FSE:4WE) ("Entourage" or the
"Company"), a Canadian producer and distributor of
award-winning cannabis products, announced today that it will file
its financial statements and management's discussion and analysis
for the fourth quarter and fiscal year ended December 31, 2023,
after market close on April 29, 2024. The Company will defer its
fourth quarter and full-year 2023 conference call to coincide with
its projected first quarter 2024 financial results, expected on or
before May 30, 2024. Filing and conference call details for the
first quarter of 2024 will be provided in a future announcement.
Company Update
The Company announced today that, in accordance
with the provisions of its omnibus equity incentive compensation
plan (the "Omnibus Plan"), the Company has
authorized the issuance of an aggregate of 1,600,000 deferred share
units (“DSUs”) to the Board of Directors of the Company as
compensation for their services for the fourth quarter of 2023 and
the first quarter of 2024 respectively. The DSUs will vest on
December 31, 2024, and March 31, 2025, respectively, and are
granted in lieu of cash compensation for services rendered during
the quarters.
About Entourage Health
Corp.
Entourage Health Corp. is the publicly traded
parent Company of Entourage Brands Corp., a licence holder
producing and distributing cannabis products for the medical and
adult-use markets. The Company owns and operates a fully licensed
26,000 sq. ft. Aylmer, ON processing facility. With its Starseed
Medicinal medical-centric brand, Entourage has expanded its
multi-channelled distribution strategy. Starseed’s industry-first,
exclusive partnership with LiUNA, the largest construction union in
Canada, along with employers and union groups, complements
Entourage's direct sales to medical patients. Entourage's elite
adult-use product portfolio includes Color Cannabis, Saturday
Cannabis – and now Dime Bag and Syndicate – sold across eight
provincial distribution agencies. Exclusive Canadian producer and
distributor of award-winning U.S.-based wellness brand Mary's
Medicinals, sold in both medical and adult-use channels. In
addition, Entourage also entered into an exclusive agreement with
Irwin Naturals, a nutraceutical and herbal supplement formulator of
branded wellness products sold across North America.
For Investor & Media
Enquiries:Catherine FlamanSenior Director, Communications
& Corporate AffairsCatherine.flaman@entouragecorp.com
Forward Looking Information
This press release contains "forward-looking information" within
the meaning of applicable Canadian securities legislation which are
based upon Entourage's current internal expectations, estimates,
projections, assumptions and beliefs and views of future events.
Forward-looking information can be identified using forward-looking
terminology such as "expect," "likely," "may," "will," "should,"
"intend," "anticipate," "potential," "proposed," "estimate" and
other similar words, including negative and grammatical variations
thereof, or statements that certain events or conditions "may,"
"would" or "will" happen, or by discussions of strategy.
The forward-looking information in this news
release is based upon the expectations, estimates, projections,
assumptions, and views of future events which management believes
to be reasonable in the circumstances. Forward-looking information
includes estimates, plans, expectations, opinions, forecasts,
projections, targets, guidance, or other statements that are not
statements of fact. Forward-looking information necessarily involve
known and unknown risks, including, without limitation, risks
associated with general economic conditions; adverse industry
events; loss of markets; future legislative and regulatory
developments; inability to access sufficient capital from internal
and external sources, and/or inability to access sufficient capital
on favourable terms; the cannabis industry in Canada generally; the
ability of Entourage to implement its business strategies;
competition; crop failure; and other risks.
Any forward-looking information speaks only as
of the date on which it is made, and, except as required by law,
Entourage does not undertake any obligation to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise. New factors emerge from
time to time, and it is not possible for Entourage to predict all
such factors. When considering this forward-looking information,
readers should keep in mind the risk factors and other cautionary
statements in Entourage's disclosure documents filed with the
applicable Canadian securities regulatory authorities and available
on SEDAR+ at www.sedarplus.ca. The risk factors and other factors
noted in the disclosure documents could cause actual events or
results to differ materially from those described in any
forward-looking information.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR
THE ADEQUACY OR ACCURACY OF THIS RELEASE
Entourage Health (TSXV:ENTG)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Entourage Health (TSXV:ENTG)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024